Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 6/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935332 | 0.91 | TBXAS1 (0.50) | TERTTBXAS1NAMPT | |
| Hydrochloric Acid SCHEMBL8108651 | 0.90 | TBXAS1 (0.51) | TERTTBXAS1NAMPT | |
| SCHEMBL9081976 | 0.85 | TERT (0.53) | TERTTBXAS1NAMPTFDPSFPR2 | |
| SCHEMBL7426540 | 0.80 | TERT (0.54) | TERTTBXAS1NAMPTFDPSFPR2 | |
| SCHEMBL17470979 | 0.79 | SMN1; SMN2 (0.52) | TERTTBXAS1NAMPTFPR2MTNR1A | |
| SCHEMBL1142559 | 0.79 | TBXAS1 (0.43) | TERTTBXAS1NAMPTFDPSFPR2 | |
| SCHEMBL13034815 | 0.78 | TERT (0.49) | TERTTBXAS1NAMPTFPR2HRH4 | |
| SCHEMBL16768654 | 0.78 | TERT (0.49) | TERTTBXAS1NAMPTFDPSFPR2 | |
| SCHEMBL16133628 | 0.78 | TERT (0.49) | TERTTBXAS1NAMPTFDPSFPR2 | |
| SCHEMBL7198930 | 0.78 | TERT (0.49) | TERTTBXAS1NAMPTFDPSFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582684-B2 | Macroporous ion exchange resins | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-09-01 | — | — | US | claimed |
| EP-0707077-B1 | Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same | ORTHO CLINICAL DIAGNOSTICS INC (US) | 2004-11-17 | — | — | EP | claimed |
| EP-0702006-B1 | Weakly basic polymerizable monomers and polymers prepared therefrom | JOHNSON & JOHNSON CLIN DIAG (US) | 2000-05-10 | — | — | EP | claimed |
| US-5582988-A | PRECIPITAION OF NUCLEIC ACID AND CATION POLYMER AT ACIDIC PH; ADJUSTMENT OF PH TO RELEASE NUCLEIC ACID | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-12-10 | — | — | US | claimed |
| US-5523368-A | Weakly basic polymerizable monomers and polymers prepared therefrom | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-06-04 | — | — | US | claimed |
| EP-0707077-A2 | Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-04-17 | — | — | EP | claimed |
| EP-0702006-A1 | Weakly basic polymerizable monomers and polymers prepared therefrom | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-03-20 | — | — | EP | claimed |
| US-12630582-B2 | Method for biomaterial purification and kits thereof | Life Technologies Corporation (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250367610-A1 | Block Copolymers Grafted to Porous Polymeric Substrate | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4543575-A1 | BLOCK COPOLYMERS GRAFTED TO POROUS POLYMERIC SUBSTRATE | Solventum Intellectual Properties Company (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-2588219-B1 | FILTER PLATE ARTICLE HAVING A WATER-ABSORBENT FILTER ASSEMBLY | NEOGEN FOOD SAFETY US HOLDCO CORP (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240059731-A1 | Method for Biomaterial Purification and Kits Thereof | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2024-02-22 | — | — | US | disclosed |
| US-20240010674-A1 | A FILTRATION UNIT AND A METHOD FOR BIOMATERIAL PURIFICATION | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2024-01-11 | — | — | US | disclosed |
| WO-2000066783-A2 | RAPID AND EFFICIENT CAPTURE OF DNA FROM SAMPLE WITHOUT USING CELL LYSING REAGENT | ORTHO-CLINICAL DIAGNOSTICS, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
| EP-0702006-B1 | Weakly basic polymerizable monomers and polymers prepared therefrom | JOHNSON & JOHNSON CLIN DIAG (US) | 2000-05-10 | — | — | EP | disclosed |
| US-5582988-A | PRECIPITAION OF NUCLEIC ACID AND CATION POLYMER AT ACIDIC PH; ADJUSTMENT OF PH TO RELEASE NUCLEIC ACID | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5523368-A | Weakly basic polymerizable monomers and polymers prepared therefrom | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0707077-A2 | Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-04-17 | — | — | EP | disclosed |
| EP-0702006-A1 | Weakly basic polymerizable monomers and polymers prepared therefrom | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| US-5434270-A | Weakly basic polymerizable monomers and polymers prepared therefrom | EASTMAN KODAK COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059731-A1 | Method for Biomaterial Purification and Kits Thereof | BMP2, ADM2, PLOD3 | TERT 1545/4885TBXAS1 2459/4885NAMPT 3388/4885 |
| US-12630582-B2 | Method for biomaterial purification and kits thereof | CD68, FIBP, BMP2 | TERT 834/4885TBXAS1 3108/4885NAMPT 3608/4885 |
| US-20240010674-A1 | A FILTRATION UNIT AND A METHOD FOR BIOMATERIAL PURIFICATION | CD68, PLAUR, BMP2 | TERT 3493/4885TBXAS1 4346/4885NAMPT 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.